Quanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025

Reuters

2025/07/28

Quanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025

Quanterix Corporation has announced the commercial launch of two novel phospho-tau assays, p-Tau 205 and p-Tau 212, aimed at advancing Alzheimer's research. These assays are designed to expand the company's portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The launch coincides with Quanterix's participation at the Alzheimer's Association International Conference $(AAIC)$ 2025, where over 55 posters and presentations featuring data utilizing its Simoa® technology will be showcased. The assays, developed on the Simoa® platform, are available for use on the HD-X or SR-X instruments or through testing at Quanterix's Accelerator Lab. The introduction of these assays is part of Quanterix's efforts to provide support for earlier detection and personalized treatment approaches for Alzheimer's disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250728299738) on July 28, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2554306775"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554306775\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554306775?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-28 19:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554306775","market":"nz","top_or_hot":-1,"title":"Quanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Quanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quanterix Corporation has announced the commercial launch of two novel phospho-tau assays, p-Tau 205 and p-Tau 212, aimed at advancing Alzheimer's research. These assays are designed to expand the company's portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The launch coincides with Quanterix's participation at the Alzheimer's Association International Conference <a href=\"https://laohu8.com/S/AAIC\">$(AAIC)$</a> 2025, where over 55 posters and presentations featuring data utilizing its Simoa® technology will be showcased. The assays, developed on the Simoa® platform, are available for use on the HD-X or SR-X instruments or through testing at Quanterix's Accelerator Lab. The introduction of these assays is part of Quanterix's efforts to provide support for earlier detection and personalized treatment approaches for Alzheimer's disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250728299738) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-28 19:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Quanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Quanterix Corporation has announced the commercial launch of two novel phospho-tau assays, p-Tau 205 and p-Tau 212, aimed at advancing Alzheimer's research. These assays are designed to expand the company's portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The launch coincides with Quanterix's participation at the Alzheimer's Association International Conference <a href=\"https://laohu8.com/S/AAIC\">$(AAIC)$</a> 2025, where over 55 posters and presentations featuring data utilizing its Simoa® technology will be showcased. The assays, developed on the Simoa® platform, are available for use on the HD-X or SR-X instruments or through testing at Quanterix's Accelerator Lab. The introduction of these assays is part of Quanterix's efforts to provide support for earlier detection and personalized treatment approaches for Alzheimer's disease.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250728299738) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDLbmHR25:1","article_id":"2554306775","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554306775","pubTimestamp":1753700460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Quanterix Corporation has announced the commercial launch of two novel phospho-tau assays, p-Tau 205 and p-Tau 212, aimed at advancing Alzheimer's research. These assays are designed to expand the company's portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The launch coincides with Quanterix's participation at the Alzheimer's Association International Conference  2025, where over 55 posters and presentations featuring data utilizing its Simoa technology will be showcased. The assays, developed on the Simoa platform, are available for use on the HD-X or SR-X instruments or through testing at Quanterix's Accelerator Lab. The introduction of these assays is part of Quanterix's efforts to provide support for earlier detection and personalized treatment approaches for Alzheimer's disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","QTRX":"Quanterix Corp"},"translate_title":"Quanterix Corporation在AAIC 2025上推出开创性的p-Tau 205和212检测以增强阿尔茨海默病研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QTRX":0.9},"content_text":"Quanterix Corporation Launches Pioneering p-Tau 205 and 212 Assays to Enhance Alzheimer's Research at AAIC 2025\n    \n\n        Quanterix Corporation has announced the commercial launch of two novel phospho-tau assays, p-Tau 205 and p-Tau 212, aimed at advancing Alzheimer's research. These assays are designed to expand the company's portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The launch coincides with Quanterix's participation at the Alzheimer's Association International Conference $(AAIC)$ 2025, where over 55 posters and presentations featuring data utilizing its Simoa® technology will be showcased. The assays, developed on the Simoa® platform, are available for use on the HD-X or SR-X instruments or through testing at Quanterix's Accelerator Lab. The introduction of these assays is part of Quanterix's efforts to provide support for earlier detection and personalized treatment approaches for Alzheimer's disease.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quanterix Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250728299738) on July 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}